[Clinical application of ibudilast for elder patients with chronic subdural hematoma].
Ibudilast, an antagonist of platelet-activating factor receptors, was administered to patients with chronic subdural hematoma (CSDH) to assess its effectiveness in preventing recurrence. The remaining volumes of subdural hematomas on brain computed tomography were measured approximately 1-2 months after using ibudilast. The hematomas were significantly smaller and there was no recurrence. Ibudilast administration may be useful in the prevention of recurrence of CSDH.